

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

News

- The EDie integration with CMT/PointClickCare was discontinued on December 31, 2023.

Registration

Some licensed providers may be registered as an IHS, Military, or VA Prescriber and would not be counted in the number registered in AWARxE (PDMP).

Portal

Number of licensed APRN's: 2,211
Controlled Substance Prescriptive Authority: 1,671
Number with DEA Registrations: 1,594
Number of PDMP Designations: 1,533
Directly Dispensing Controlled Substances: 96

AWARxE (PDMP)

Number registered in the PDMP: 1,356

Use – Review Compliance

Federally Scheduled II – III controlled substances, over a three-day supply (emergency, surgical and oncology specialties are omitted). The database does not capture treatment codes and is therefore not able to account for prescription(s) not reviewed due to some of the exemptions in AS 17.30.200(k)(4)(A).

Q3 2023: 45.38%
Q4 2023: 44.08%

Delinquent Reporters

An email was sent to providers clarifying their dispensing status. We will follow up with those who are directly dispensing to ensure they understand how and when to report.

Gateway

APRN's conducted 36,720 patient reviews in Q4 2023. This table shows the number of reviews being performed through Gateway vs. AWARxE web-based platform. Approximately **64%** of reviews are coming through Gateway Integrations.

	Gateway	AWARxE	Total
October	8,378	4,745	13,123
November	7,911	4,279	12,190
December	7,196	4,211	11,407

Recommendations

- Promote increased reviewing. Mandatory review applies to non-refillable federally scheduled II – III controlled substances over a three-day supply (for further exemptions see AS 17.30.200(k)).
- Remind providers who are directly dispensing to report daily, including zero reports.